Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
- Referrals to patient-related programs or resources
- Donations, website, or event-related assistance
- Tobacco-related topics
- Volunteer opportunities
- Cancer Information
For medical questions, we encourage you to review our information with your doctor.
Hormone Therapy for Uterine Sarcomas
Hormone therapy is the use of hormones or hormone-blocking drugs to treat cancer. Part of diagnosing uterine sarcoma includes tests that check the cancer cells to see if they have receptors (proteins) where hormones can attach. If they do have these receptors (estrogen and/or progesterone ), hormone treatment might be a good option. Hormone therapy is mainly used to treat low-grade endometrial stromal sarcomas (ESS) and is rarely used for the other types of uterine sarcomas.
Aromatase inhibitors
After the ovaries are removed, or aren't working (after menopause), some estrogen is still made in fat tissue. This becomes the body's main source of estrogen. Drugs called aromatase inhibitors can stop this estrogen from being made. Examples of aromatase inhibitors include letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin). These drugs are most often used to treat breast cancer, but they are also helpful in treating low-grade endometrial stromal sarcoma, adenosarcoma, or other sarcomas that have estrogen and/or progesterone receptors.These drugs are only useful for those whose ovaries have been removed or no longer work (like after menopause).
Side effects can include any of the symptoms of menopause, such as hot flashes and vaginal dryness, as well as joint/muscle pain. If they are taken for a long time (years), these drugs can weaken bones, sometimes leading to osteopenia or osteoporosis.
Progestins
Progestins are drugs that act like the hormone progesterone. The progestins used most often to treat estrogen-positive and/or progesterone-positive uterine sarcomas are megestrol (Megace) and medroxyprogesterone (Provera). Both of these drugs are pills you take every day.
Side effects can include increased blood sugar levels in patients with diabetes. Hot flashes, night sweats, and weight gain (from fluid retention and an increased appetite) also occur. Rarely, serious blood clots can happen in people taking progestins.
Gonadotropin-releasing hormone agonists
Gonadotropin-releasing hormone (GNRH) agonists are drugs used to lower estrogen levels in women who are premenopausal (are still having periods or have not gone through menopause). Before menopause, almost all of a woman's estrogen is made by the ovaries. These drugs keep the ovaries from making estrogen. Examples of GNRH agonists include goserelin (Zoladex) and leuprolide (Lupron). These drugs are given as a shot into a muscle every 1 to 3 months.
Side effects can include any of the symptoms of menopause, such as hot flashes and vaginal dryness. If they are taken for a long time, these drugs can weaken bones, sometimes leading to osteoporosis.
More information about hormone therapy
To learn more about how hormone therapy is used to treat cancer, see Hormone Therapy.
To learn about some of the side effects listed here and how to manage them, see Managing Cancer-related Side Effects.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Alektiar KM, Abu-Rustum NR, and Fleming GF. Chapter 75- Cancer of the Uterine Body. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 11th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2019.
Benson C, Miah AB. Uterine sarcoma -- current perspectives. Int J Womens Health. 2017;9:597-606.
Boggess JF, Kilgore JE, and Tran AQ. Ch. 85 – Uterine Cancer. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa. Elsevier; 2020.
Dizon DS, Birrer MJ. Advances in the diagnosis and treatment of uterine sarcomas. Discov Med. 2014;17(96):339-345.
Gaillard S and Secord AA. Staging, treatment, and prognosis of endometrial stromal sarcoma and related tumors and uterine adenosarcoma. In: Chakrabarti A and Vora SR, eds. UpToDate. Waltham, Mass.: UpToDate, 2021. https://www.uptodate.com. Accessed June 13, 2022.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasms, Version 1.2022 – November 4, 2021. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf on June 13, 2022.
Last Revised: September 20, 2022
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.